Language:

A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study

Bone (New York, N.Y.), 2011-10, Vol.49 (4), p.605 [Peer Reviewed Journal]

Copyright © 2011 Elsevier Inc. All rights reserved. ;EISSN: 1873-2763 ;DOI: 10.1016/j.bone.2011.07.011 ;PMID: 21784190

Digital Resources/Online E-Resources

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study
Author: Matsumoto, Toshio ; Ito, Masako ; Hayashi, Yasufumi ; Hirota, Takako ; Tanigawara, Yusuke ; Sone, Teruki ; Fukunaga, Masao ; Shiraki, Masataka ; Nakamura, Toshitaka
Subjects: Aged ; Aged, 80 and over ; Bone Density - drug effects ; Bone Remodeling - drug effects ; Cholecalciferol - analogs & derivatives ; Double-Blind Method ; Female ; Hormones - blood ; Humans ; Incidence ; Japan - epidemiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Osteoporotic Fractures - blood ; Osteoporotic Fractures - drug therapy ; Osteoporotic Fractures - physiopathology ; Osteoporotic Fractures - prevention & control ; Risk Factors ; Spinal Fractures - blood ; Spinal Fractures - drug therapy ; Spinal Fractures - epidemiology ; Spinal Fractures - physiopathology ; Treatment Outcome ; Vitamin D - analogs & derivatives ; Vitamin D - blood ; Vitamin D - pharmacology ; Vitamin D - therapeutic use
Is Part Of: Bone (New York, N.Y.), 2011-10, Vol.49 (4), p.605
Description: Eldecalcitol is an analog of 1,25-dihydroxyvitamin D(3) that improves bone mineral density; however, the effect of eldecalcitol on the risk of fractures is unclear. The objective of this study is to examine whether eldecalcitol is superior to alfacalcidol in preventing osteoporotic fractures. This trial is registered with ClinicalTrials.gov, number NCT00144456. This 3 year randomized, double-blind, active comparator, superiority trial tested the efficacy of daily oral 0.75 μg eldecalcitol versus 1.0 μg alfacalcidol for prevention of osteoporotic fractures. 1054 osteoporotic patients 46 to 92 years old were randomly assigned 1:1 to receive eldecalcitol (n=528) or alfacalcidol (n=526). Patients were stratified by study site and serum 25-hydroxyvitamin D level. Patients with low serum 25-hydroxyvitamin D levels (<50 nmol/L) were supplemented with 400 IU/day vitamin D(3). Primary end point was incident vertebral fractures. Secondary end points included any non-vertebral fractures and change in bone mineral density and bone turnover markers. Compared with the alfacalcidol group, the incidence of vertebral fractures was lower in eldecalcitol group after 36 months of treatment (13.4 vs. 17.5%; hazard ratio, 0.74; predefined 90% confidence interval [CI], 0.56-0.97). Eldecalcitol reduced turnover markers and increased bone mineral density more strongly than alfacalcidol. Eldecalcitol reduced the incidence of three major non-vertebral fractures, which was due to a marked reduction in wrist fractures by a post-hoc analysis (1.1 vs. 3.6%; hazard ratio, 0.29; 95% CI, 0.11-0.77). Among the adverse events, the incidence of increase in serum and urinary calcium was higher in the eldecalcitol group, without any difference in glomerular filtration rate between the two groups. Eldecalcitol is more efficacious than alfacalcidol in preventing vertebral and wrist fractures in osteoporotic patients with vitamin D sufficiency, with a safety profile similar to alfacalcidol.
Publisher: United States
Language: English
Identifier: EISSN: 1873-2763
DOI: 10.1016/j.bone.2011.07.011
PMID: 21784190
Source: MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study

Copyright © 2011 Elsevier Inc. All rights reserved. ;EISSN: 1873-2763 ;DOI: 10.1016/j.bone.2011.07.011 ;PMID: 21784190

Searching Remote Databases, Please Wait